Abstract
Prehypertension (systolic blood pressure 120-139 or diastolic blood pressure 80-89 mm Hg) confers a risk of progression to hypertension, impairment of cognitive function, increased left ventricular mass, risk of end-stage renal disease, and an association with arteriosclerosis. Recent studies provide data that could support the rationale for treating prehypertensives subjects with antihypertensive medications in addition to lifestyle modification, especially if they have concomitant cardiovascular risk factors.
Keywords:
Cognitive function; drug treatment; end-stage renal disease; left ventricular hypertrophy.
Copyright © 2017 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.
MeSH terms
-
Antihypertensive Agents / therapeutic use*
-
Arteriosclerosis / epidemiology
-
Arteriosclerosis / physiopathology*
-
Blood Pressure / drug effects
-
Blood Pressure / physiology
-
Cognitive Dysfunction / epidemiology
-
Cognitive Dysfunction / physiopathology*
-
Disease Progression
-
Humans
-
Hypertension / drug therapy
-
Hypertension / epidemiology
-
Hypertension / genetics
-
Hypertension / physiopathology*
-
Hypertrophy, Left Ventricular / drug therapy
-
Hypertrophy, Left Ventricular / epidemiology
-
Hypertrophy, Left Ventricular / physiopathology*
-
Incidence
-
Kidney Failure, Chronic / epidemiology
-
Kidney Failure, Chronic / physiopathology*
-
Life Style
-
Prehypertension / drug therapy
-
Prehypertension / genetics
-
Prehypertension / physiopathology*
-
Risk Factors